Trial reportThe Journal of allergy and clinical immunology2010
Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.
Trial report in The Journal of allergy and clinical immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it, 113 citations in OpenAlex.
- Mepolizumab in Hypereosinophilic Syndrome: A Systematic Review and Meta-analysis.Clinics (Sao Paulo, Brazil) · 2021Pooled it
- Long-Term Efficacy and Safety of Benralizumab Treatment for PDGFRA-Negative Hypereosinophilic Syndrome.The journal of allergy and clinical immunology. In practice · 2025Trial
- Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial.The Journal of allergy and clinical immunology · 2020Trial
- Benralizumab forThe New England journal of medicine · 2019Trial
- Episodic angioedema with eosinophilia (Gleich syndrome) is a multilineage cell cycling disorder.Haematologica · 2015Trial
- Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes.The Journal of allergy and clinical immunology · 2013Trial
- Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome.The journal of allergy and clinical immunology. In practiceTrial
- IL-5 CAR-T cell therapy induces effective remission in hypereosinophilic disorders.Journal of hematology & oncology · 2026Article
- Expansion of multiple CD4The Journal of allergy and clinical immunology · 2025Article
- Paradoxical Use of Benralizumab in Reactive Hypereosinophilia from Toxocariasis and Tuberculosis Co-Infection-Case Report and Literature Review.International journal of molecular sciences · 2025Review
- Improving patient outcomes: Mepolizumab's impact in IL-5-mediated diseases.Lung India : official organ of Indian Chest Society · 2025Article
- Biologics in Hypereosinophilic Syndrome and Eosinophilic Granulomatosis with Polyangiitis.Immunology and allergy clinics of North America · 2024Review
- Biologic therapy in rare eosinophil-associated disorders: remaining questions and translational research opportunities.Journal of leukocyte biology · 2024Review
- Review
- Mepolizumab incompletely suppresses clinical flares in a pilot study of episodic angioedema with eosinophilia.The Journal of allergy and clinical immunology · 2024Article
- Biologics and Hypereosinophilic Syndromes: Knowledge Gaps and Controversies.The journal of allergy and clinical immunology. In practice · 2023Article
- HES and EGPA: Two Sides of the Same Coin.Mayo Clinic proceedings · 2023Review
- Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases.Frontiers in immunology · 2023Review
- Approach to the patient with suspected hypereosinophilic syndrome.Hematology. American Society of Hematology. Education Program · 2022Review
- Controversies in Allergy: The Potential Role of Biologics as First-Line Therapy in Eosinophilic Disorders.The journal of allergy and clinical immunology. In practice · 2022Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
Abstract
backgroundMepolizumab, a monoclonal anti-IL-5 antibody, is an effective corticosteroid-sparing agent for patients with Fip1-like 1/platelet-derived growth factor receptor α fusion (F/P)-negative hypereosinophilic syndrome (HES). Lymphocytic variant hypereosinophilic syndrome (L-HES) is characterized by marked overproduction of IL-5 by dysregulated T cells.
objectiveTo determine whether patients with L-HES respond to mepolizumab in terms of corticosteroid tapering and eosinophil depletion to the same extent as corticosteroid-responsive F/P-negative patients with HES and a normal T-cell profile.
methodsPatients enrolled in the mepolizumab trial were evaluated for L-HES on the basis of T-cell phenotyping and T-cell receptor gene rearrangement patterns, and their serum thymus-and-activation-regulated chemokine (TARC) levels were measured. Response to treatment was compared in patient subgroups based on results of these analyses.
resultsLymphocytic variant HES was diagnosed in 13 of 63 patients with HES with complete T-cell assessments. The ability to taper corticosteroids on mepolizumab was similar in patients with L-HES and those with a normal T-cell profile, although a lower proportion of patients with L-HES maintained eosinophil levels below 600/μL. Increased serum TARC levels (>1000 pg/mL) had no significant impact on the ability to reduce corticosteroid doses, but a lower proportion of patients with elevated TARC achieved eosinophil control on mepolizumab.
conclusionMepolizumab is an effective corticosteroid-sparing agent for patients with L-HES. In some cases however, eosinophil levels remain above 600/μL, suggesting incomplete neutralization of overproduced IL-5 or involvement of other eosinophilopoietic factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.